(Headquarters: Nagoya, Aichi Prefecture, Japan; hereinafter "Kowa"), today announced that on June 11, it received ...

WASHINGTON, DC — Measures of liver stiffness remained stable or improved in patients with primary biliary cholangitis (PBC) after 36 months of treatment with seladelpar (Livdelzi) based on new data ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi ® (seladelpar) ...

The authors of this review assess the role of endoscopic retrograde cholangiopancreatography (ERCP) and emerging endoscopic techniques in the diagnosis, treatment, and management of primary sclerosing ...

Please provide your email address to receive an email when new articles are posted on . More patients on elafibranor compared with placebo achieved biochemical response, with a 47% treatment benefit.

—A recent study provides genetic evidence linking a higher body mass index (BMI) to an increased risk of primary biliary cholangitis and autoimmune hepatitis but a decreased risk of primary sclerosing ...

Elafibranor, a dual peroxisome proliferator-activated receptor (PPAR) alpha and delta agonist, appears to be a safe and effective treatment of primary biliary cholangitis, according to a new clinical ...

A major retrospective study shows that people with blood group A face a higher likelihood of autoimmune liver disease, especially primary biliary cholangitis, while those with blood group B appear ...

While you may be living with fatigue, itching, brain fog, and joint pain — symptoms of primary biliary cholangitis (PBC) — others might not realize their impact. Over time, social isolation, ongoing ...

Content developed independently by our editors and supported by our partners. The road to a medical diagnosis is not always a simple one—something Carrington Garvin, 24, discovered when she began ...